Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers antihistamine; muscle relaxant; diuretic; iron deficiency; anti-diabetic, including Metformin HCL; anti-fungal, ulcer, malaria, and inflammatory; iodine supplement; analgesics; antacids; potassium and sodium iodide; and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and 3,4,5 - trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; 3,4,5 - trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. The company was incorporated in 1989 and is based in Mumbai, India.
Metrics to compare | AURL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAURLPeersSector | |
---|---|---|---|---|
P/E Ratio | 140.8x | 28.8x | −0.7x | |
PEG Ratio | −1.61 | 0.16 | 0.00 | |
Price/Book | 3.2x | 3.5x | 2.6x | |
Price / LTM Sales | 8.4x | 2.4x | 3.4x | |
Upside (Analyst Target) | - | 18.6% | 37.6% | |
Fair Value Upside | Unlock | 1.4% | 5.3% | Unlock |